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Edited by Felix WielandAbstract Calcium/calmodulin-dependent protein kinase I-a
(CaMKI-aÞ is a ubiquitous cytosolic enzyme that phosphorylates
a number of nuclear proteins in vitro and has been implicated in
transcriptional regulation. We report that cytoplasmic localiza-
tion of CaMKI-a depends on CRM1-mediated nuclear export
mediated through a Rev-like nuclear export signal in the
CaMKI-a regulatory domain. Interaction of CaMKI-a with a
CRM1 complex in vitro is enhanced by incubation with calcium/
calmodulin. Translocation of CaMKI-a into the nucleus involves
a conserved sequence located within the catalytic core. Mutation
of this sequence partially blocks nuclear entry of an export-
impaired mutant of CaMKI-a.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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protein kinase I1. Introduction
Calcium/calmodulin-dependent protein kinase I (CaMKI)
has been implicated in several cellular processes including
embryonic development [1], cell division [2–4], hormone pro-
duction [5], neurite outgrowth [6], myogenesis and actin ﬁla-
ment organization [7,8] and transcriptional activation [9,10]. A
number of substrates have been identiﬁed for CaMKI in-
cluding synapsin I and II [11], the cystic ﬁbrosis transmem-
brane conductance regulator [12], myosin II regulatory light
chain kinase [8], cAMP response element-binding protein
(CREB) [13], activating transcription factor (ATF-1) [14], hi-
stone deacetylases 4 and 5 [7], and the translation initiation
factor eIF4GII [10]. Yet, the physiological role of CaMKI is
not well understood.
Multiple isoforms of CaMKI have been identiﬁed with dis-
tinct subcellular and tissue distributions. CaMKI-a has a
broad tissue distribution and is primarily cytosolic, although
nuclear localization of CaMKI-a has been suggested in a* Corresponding author. Fax: +1-203-737-2043.
E-mail address: marina.picciotto@yale.edu (M.R. Picciotto).
Abbreviations: CaMK, calcium/calmodulin-dependent protein kinase;
CaM, calmodulin; Ca2þ, calcium; LMB, leptomycin B; NES, nuclear
export signal; NLS, nuclear localization signal
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doi:10.1016/j.febslet.2004.04.042subset of neurons [15,16]. CaMKI-b1 and -b2 localize to both
the cytoplasm and nucleus, and are found in liver, heart, lung,
kidney, spleen and testes (b1), and brain (b2) [17,18]. CaMKI-
c1 and -c2 appear to be anchored to Golgi and plasma
membranes in neurons [19,20]. Recently, a sixth isoform
(CaMKI-d) has also been identiﬁed [21]. The tissue distribu-
tion and subcellular localization of CaMKI isoforms are likely
to be critical in determining their physiological roles. Since
calmodulin (CaM) kinases have been proposed to play a role
in nuclear processes [9,10], the regulation of nuclear traﬃcking
of CaMKI isoforms is of interest.
Here, we report the identiﬁcation of a nuclear export signal
(NES) in the regulatory domain of CaMKI-a and demonstrate
that nuclear export is mediated through CRM1. Association of
CaMKI-a with a CRM1 complex is enhanced in the presence
of calcium (Ca2þ)/CaM, suggesting that activation of the ki-
nase may facilitate its nuclear export. We also report identiﬁ-
cation of an amino acid sequence (K293R294) in the catalytic
core of CaMKI-a that appears to play a role in nuclear import.2. Materials and methods
2.1. Cell culture and transfection
PC12 cells were maintained on collagen (Upstate Biotechnologies) in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Life Technologies)
supplemented with 10% horse serum/5% fetal bovine serum/100 lg/ml
penicillin–streptomycin. For microscopic analysis, PC12 cells were
plated on poly L-lysine- (Peptide Institute Inc.) and laminin-coated
(Invitrogen) glass coverslips. Cos7 cells were maintained in DMEM
supplemented with 10% fetal bovine serum/100 lg/ml penicillin–
streptomycin. Transfections were performed using FuGene 6 (Roche).
2.2. Plasmid construction
GFP-fusion plasmids were generated by subcloning PCR-ampliﬁed
full length CaMKI-a (CaMKI374) and CaMKI-a truncations (CaM-
KI362, CaMKI344, CaMKI322, CaMKI305, CaMKI296, and CaM-
KI293) into the BglII and KpnI sites of pEGFPC-1 (Clontech).
Mutations of full length and truncated CaMKI-a were generated using
the QuickChange kit (Stratagene). pC1-HA-CRM1 and pQE32-
RanQ69L [22,23] were gifts from Dr. Mark Hannink (University of
Missouri).
2.3. Subcellular localization of CaMKI-a
Transfected PC12 cells were examined by live cell ﬂuorescence mi-
croscopy after the following treatments: 2 h incubation with 200 ng/ml
leptomycinB (LMB;Sigma), 30minwith 2mMCaCl2/1mMMgCl2 and
either 40 mMKCl or 4 lM ionomycin (Molecular Probes), 30 min with
10 lMKN62 (Calbiochem), or 1 h with 10 lMBAPTA-AM (Molecular
Probes). Endogenous CaMKI-a was examined by immunoﬂuorescenceation of European Biochemical Societies.
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without pretreatment with 200 ng/ml LMB. Cells were ﬁxed with 4%
paraformaldehyde, permeabilized with 0.1% Triton X-100, and incu-
bated for 1 h with 1:500 CC77 antibody [16] followed by 30 min incu-
bation with 1:1000 Alexa Fluor anti-rabbit antibody (Molecular
Probes). Images were captured at 400 magniﬁcation.
The cytoplasmic and nuclear density of GFP ﬂuorescence within
individual cells was determined using Image J software (NIH). The
total number of pixels was calculated for an equivalent area in both
cytoplasm and nucleus (corrected for background ﬂuorescence) for
each cell examined. The resulting values were used to calculate the
cytoplasmic:nuclear pixel density ratio (C:N) for each cell in an ex-
perimental group. An experimental group consisted of a minimum of
ﬁve cells from the same transfection or 15 cells per condition in
immunoﬂuorescence experiments. The mean C:N ratios from three
experimental groups (P15 cells total) were averaged to determine the
mean ratio for each expressed protein.
2.4. In vitro binding assay
The protocol for in vitro binding of GST-CaMKI-a to HA-CRM1
was modiﬁed from [22]. Crude lysate from Cos7 cells expressing HA-
CRM1 was incubated for 2 h at 4 C with anti-HA aﬃnity matrix
(Covance). The HA-CRM1-bound matrix was washed, divided evenly
into three tubes, and incubated overnight with GST-CaMKI-a (with or
without a 10 min preincubation with 2 mM CaCl2 and 20 lg/ml CaM
(Sigma)) in the absence or presence of His-RAN-GTP. After washing,
samples were eluted with SDS–PAGE sample buﬀer.
2.5. SDS–PAGE and Western-blot analysis
Samples were separated using SDS–PAGE (10% acrylamide) and
transferred to nitrocellulose. HA-CRM1 was detected with mouse
monoclonal anti-HA antibody (Covance, 1:200). GST-CaMKI-a was
detected using rabbit polyclonal anti-GST antibody (Santa Cruz,
1:2000). His-RAN was detected with a rabbit polyclonal Ran antibody
(Covance, 1:2000). Secondary antibodies were diluted 1:2000.
2.6. Statistical analysis
Statistical analysis was by ANOVA followed by the Tukey HSD
post hoc test. P < 0:05 was considered signiﬁcant.Fig. 1. Subcellular distribution of CaMKI-a. (A) Fluorescence images
of cells expressing GFP-CaMKI374 (374) and GFP-CaMKI293 (293).
(B) Schematic representation of C-terminal truncations of CaMKI-a.
(C) Fluorescence images of cells expressing GFP-CaMKI362 (362),
GFP-CaMKI344 (344), GFP-CaMKI322 (322), GFP-CaMKI305
(305), and GFP-CaMKI296 (296). (D) Cytoplasmic:nuclear ratios of
GFP ﬂuorescence in transfected cells. Error bars: ±S.D. ANOVA:
F ð6; 115Þ ¼ 69:59. Post hoc tests revealed that C:N ratios of 374, 362,
344 and 322 were signiﬁcantly diﬀerent from those of 305, 296, 293
ðP < 0:001Þ.3. Results
3.1. Subcellular distribution of CaMKI-a
Like the native protein [16], CaMKI-a, fused at itsN-terminus
to green ﬂuorescent protein (GFP-CaMKI374), localized to the
cytoplasm of transfected cells. In contrast, CaMKI-a truncated
to amino acid 293 (GFP-CaMKI293) was found throughout the
nucleus and cytoplasm (Fig. 1A). To ascertain the eﬀect of the
autoinhibitory domain and C-terminal sequences on localiza-
tion of CaMKI-a, a series of C-terminal truncations were gen-
erated and fused to GFP (Fig. 1B). Truncation to residue 362
(GFP-CaMKI362) removed a C-terminal proline-rich domain.
Truncation to amino acids 344 and 322 (GFP-CaMKI344 and
GFP-CaMKI322) left the autoinhibitory and CaM binding
domains intact. Truncation to residue 305 (GFP-CaMKI305)
deleted the CaM binding domain but not the autoinhibitory
domain, resulting in a constitutively inactive enzyme [24]. Fur-
ther truncation to amino acids 296 and 293 (GFP-CaMKI296
and GFP-CaMKI293) removed the autoinhibitory domain,
generating CaM-independent, constitutively active forms of
CaMKI-a [24].
Two distinct localization patterns were observed for
CaMKI-a truncations. GFP-CaMKI374, -CaMKI362,
-CaMKI344, and -CaMKI322 localized to the cytoplasm,
whereas GFP-CaMKI305, -CaMKI296, and -CaMKI293
were distributed in both the cytoplasm and nucleus (Figs. 1A,
C and D). These data suggested that the region betweenresidues 305 and 322 is critical for nuclear exclusion of
CaMKI-a.
3.2. CaMKI-a contains a NES and is exported by CRM1
Examination of residues 305–322 revealed a putative NES
(315VVRHMRKLQL321) similar to the recognized consensus
(LXð1–3ÞLXð2–3ÞLXL) of the Rev-like NES [25,26] (Fig. 2A). To
determine whether this sequence serves as a functional NES,
Fig. 2. Identiﬁcation of a NES in CaMKI-a. (A) Comparison of
consensus NES sequence with residues 312–321 in CaMKI-a. (B)
Immunoﬂuorescence images of endogenous CaMKI in the absence
or presence of LMB. (C) Fluorescence images of cells expressing
GFP-CaMKI-a proteins in the absence or presence of LMB. (D)
Cytoplasmic:nuclear ratios of CaMKI distribution in the absence or
presence of LMB. Abbreviations as in Fig. 1. Black: no treatment;
white: 2 h incubation with 200 ng/ml LMB. Error bars: ±S.D.
ANOVA: F ð7; 252Þ ¼ 62:11. Post hoc tests revealed a signiﬁcant
eﬀect of LMB treatment for endogenous CaMKI (Endog), 374, 362,
344, and 322 ðP < 0:001Þ; GFP-CAMKIL319A;L321A (L319AL321A)
was signiﬁcantly diﬀerent from 374 ðP < 0:001Þ. (E) Western-blot
analysis of in vitro binding of GST-CaMKI-a to HA-CRM1 sup-
porting the idea that there is an interaction of HA-CRM1, RAN-
GTP and GST-CaMKI-a and showing the eﬀect of preincubation
with Ca2þ/CaM.
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alanine to generate GFP-CaMKIL319A;L321A. The mutant pro-
tein displayed uniform cytoplasmic and nuclear localization
within transfected cells (Figs. 2C and D).
Cells were treated with LMB, a fungicide that binds to and
inhibits the export activity ofCRM1.LMB treatment resulted in
increased nuclear localization of endogenous CaMKI (Figs. 2B
and D) and a uniform distribution of GFP-CaMKI374,
-CaMKI362, -CaMKI344, and -CaMKI322 in the cytoplasm
and nucleus of transfected cells (Figs. 2C andD), supporting the
idea that CaMKI-a is exported from the nucleus in a CRM1-
dependent manner. LMB treatment of cells expressing GFP-
CaMKI305, -CaMKI296, -CaMKI293, or -CaMKIL319A;L321A
did not alter localization of these proteins, suggesting that the
NES located between residues 315 and 321 is responsible for the
cytoplasmic localization of CaMKI-a.
The ability of CaMKI-a to interact with CRM1 was ex-
amined in vitro. GST-CaMKI-a was incubated with HA-
tagged CRM1 bound to an anti-HA aﬃnity matrix in the
presence or absence of RAN-GTP (a requisite cofactor for
binding of CRM1 to NES-containing proteins) and Ca2þ/
CaM. GST-CaMKI-a did not bind CRM1 in the absence of
RAN-GTP (Fig. 2E). Preincubation of GST-CaMKI-a with
Ca2þ/CaM increased binding of GST-CaMKI-a to CRM1
(Fig. 2E), suggesting that activation of CaMKI-a would fa-
cilitate its export from the nucleus. Although an equal volume
of HA-CRM1 bound matrix was used for each experimental
condition, variations in the amount of HA-CRM1 eluted from
the matrix were apparent (Fig. 2E). The increase in GST-
CaMKI-a bound to the matrix in the presence of Ca2þ/CaM
are seen despite variations in HA-CRM1.
3.3. Identiﬁcation of a basic amino acid sequence involved in
CaMKI-a nuclear import
Three basic amino acid motifs (K40R41, K53K54, and
K263R264) were mutated to alanine. These mutations were
made on the GFP-CaMKIL319A;L321A background, since only
low levels of CaMKI are observed in the nucleus without these
mutations. While neither GFP-CaMKIL319A;L321A;K40A;R41A nor
GFP-CaMKIL319A;L321A;K53A;K54A displayed an altered distri-
bution, GFP-CaMKIL319A;L321A;K263A;R264Awas partially, but
signiﬁcantly, excluded from the nucleus (Figs. 3A and B),
suggesting that K263R264 may be involved in nuclear import of
CaMKI-a.
3.4. Kinase activity and nuclear export
To determine the subcellular distribution of catalytically
inactive forms of CaMKI-a, the localization patterns of
GFP-CaMKI374K49A and GFP-CaMKI293K49A were exam-
ined. Residue K49 is required for kinase activity and muta-
tion of this residue to alanine results in a catalytically
inactive kinase [27]. This mutation did not alter subcellular
distribution of either form of CaMKI-a (Figs. 4A and B),
suggesting that activity alone is not enough to determine its
localization.
In vitro analysis showed that the amount of CaMKI-a
associated with CRM1 increased in the presence of Ca2þ/
CaM. To test whether kinase activation might lead to in-
creased export in cell culture, the subcellular localization of
GFP-CaMKI374 (in transfected cells) or endogenous CaM-
KI-a was examined in cells treated with KCl or ionomycin
(Figs. 4C and D). No diﬀerence in subcellular distribution
Fig. 3. Identiﬁcation of a basic amino acid sequence involved in
CaMKI-a nuclear translocation. (A) Fluorescence images of cells
expressing GFP-CaMKIL319A;L321A (L319AL321A), CaM
KIL319A;L321A;K40A;R41A (K40AR41A), CaMKIL319A;L321A;K53A;K54A
(K53AK54A), CaMKIL319A;L321A;K263A;R264A (K263AR264A), and
GFP-CaMKI374 (374). (B) C:N ratios of GFP ﬂuorescence in trans-
fected cells. Error bars: ±S.D. ANOVA: F ð4; 87Þ ¼ 50:74. Post hoc test
revealed that L319AL321A, K40AR41A, and K53AK54A were sig-
niﬁcantly diﬀerent from 374 and K263AR264A ðP < 0:004Þ.
K263AR264A was signiﬁcantly diﬀerent from 374 ðP < 0:001Þ.
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the nucleus in untreated cells, so an increase in nuclear ex-
port would not be easily detected. Treatment with the in-
tracellular calcium chelator BAPTA-AM resulted in a very
small but signiﬁcant decrease in C:N ratios in both endog-
enous CaMKI and transfected GFP-CaMKI374 compared
to untreated cells, and the CaM kinase inhibitor KN62
slightly decreased C:N ratios for GFP-CaMKI374, although
it does not appear that these agents substantially inhibit
nuclear export of CaMKI-a (Figs. 4C and D). Similar ex-
periments in transfected cells expressing GFP-
CaMKIL319A;L321A (Figs. 4C and D), or when endogenous
CaMKI was examined in untransfected cells preincubated
with LMB (not shown), showed no changes in CaMKI-a
localization. These results suggest that nuclear import is not
signiﬁcantly regulated by kinase activation.4. Discussion
The best characterized NES are short leucine-rich peptides
containing 4–5 hydrophobic residues. Mutational analyses of
NES have shown that the hydrophobic residues, particularly
leucines in the C-terminal portion of the NES, are required
for nuclear export [25,26]. We have identiﬁed a NES in
CaMKI-a with the sequence 312VVRHMRKLQL321. Muta-
tion of leucines 319 and 321 to alanine resulted in uniform
distribution of the kinase in the nucleus and cytoplasm,
suggesting that these residues are critical for nuclear export of
CaMKI-a.
Export of NES-containing proteins is mediated primarily
through CRM1, which binds to NES-cargoes cooperatively
with RAN-GTP. After transport to the cytoplasm, hydrolysis
of RAN-GTP causes dissociation of the trimer and release of
the cargo [28,29]. LMB inhibits CRM1-mediated export by
binding to CRM1 and preventing its interaction with NES-
cargo. LMB treatment of cells expressing GFP-CaMKI-a re-
sulted in uniform distribution of CaMKI-a. Thus, nuclear
export of CaMKI-a is likely mediated through CRM1.
The CaM-binding domain of CaMKI-a extends from amino
acids 294 to 315 and might partially overlap the NES. For this
reason, we initially hypothesized that CRM1 and CaM might
compete for binding to CaMKI-a. Instead, binding of CaM-
KI-a to CRM1 in vitro was enhanced in the presence of Ca2þ/
CaM, suggesting that CaM and CRM1 may have non-over-
lapping binding sites. These results are likely explained by
conformational changes that occur upon binding of Ca2þ/
CaM to CaMKI-a. In the absence of Ca2þ/CaM, the CaM-
binding domain interacts with the catalytic domain and the
NES may be less accessible [30,31]. Upon CaM binding, the
conformational changes that remove the regulatory domain
from the catalytic site potentially make the NES more acces-
sible to CRM1, thus facilitating nuclear export of activated
CaMKI-a.
Previous studies demonstrated that truncated, constitutively
active CaMKI could phosphorylate nuclear proteins in neu-
ronal cultures [14], suggesting that activation might play a role
in nuclear access; however, in these previous studies, truncat-
ing CaMKI to generate the constitutively active form deleted
the NES. The current study demonstrates that activity alone
cannot account for the localization of CaMKI-a, since inac-
tivation of the kinase by mutation of K49 or activation with
KCl or ionomycin did not signiﬁcantly aﬀect localization. This
contrasts with recent studies of CaMKIV, whose catalytic
activity is needed for nuclear entry [32].
A comparison of the regulatory domains of CaMKI-a with
other isoforms of CaMKI or CaMKIV shows that cytosolic
CaMKI-c/CKLiK [19,20,33] and CaMKI-d [21] also contain
leucine-rich, NES-like sequences in their regulatory domains
(Fig. 5). In contrast, this domain is not conserved in CaMKIV,
which is known to localize to the nucleus in many neuronal cell
types [34]. CaMKI-b, which has a relatively uniform cellular
distribution, has a glutamine in place of the C-terminal leucine
within this domain [17] (Fig. 5). It is not yet known whether
this single residue change could account for the localization
pattern of CaMKI-b.
Classical nuclear localization signals (NLS) are lysine and
arginine-rich motifs arranged as a single stretch (for example,
the PKKKRKV NLS of the SV40 large T antigen) or as two
short stretches separated by a ﬂexible region (such as the bi-
Fig. 4. Role of kinase activity in nucleocytoplasmic transport. (A) Fluorescence images of cells expressing GFP-CaMKI374 (374), GFP-
CaMKI374K49A (374K49A), GFP-CaMKI293 (293), and GFP-CaMKI293K49A (293K49A). (B) C:N ratios of GFP ﬂuorescence in transfected cells.
Error bars: ±S.D. ANOVA: F ð3; 87Þ ¼ 110:91 (no signiﬁcant eﬀect of K49A mutation). (C) Fluorescence images of cells expressing GFP-CaMKI374
or GFP-CaMKIL319AL321A and immunoﬂuorescence images of endogenous CaMKI (Endog) in cells after no treatment or treatment with KCl,
ionomycin, KN62 or BAPTA-AM. (D) C:N ratios of experimental conditions shown in C. Black (GFP-CaMKI374), white (GFP-
CaMKIL319A;L321A), and gray (endogenous). Error bars: ±S.D. ANOVA F ð9; 263Þ ¼ 48:548. Post hoc tests revealed a signiﬁcant eﬀect of treatment
with BAPTA-AM or KN62 on the GFP-CaMKI374 construct (P < 0:002Þ, and a signiﬁcant eﬀect of treatment with BAPTA-AM on endogenous
CaMKI ðP < 0:01Þ.
Fig. 5. Comparison of NES-like sequences of CaMK isoforms.
Alignment of the consensus NES with the NES of CaMKI-a and the
corresponding sequence of CaMKI-a, -b, -c, and -d and CaMKIV.
Conserved leucines within the consensus sequence and corresponding
amino acids in CaMK isoforms are highlighted with gray boxes.
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[35]. Examination of the primary sequence of CaMKI-a re-
vealed a stretch of basic amino acids extending from residues
298 to 307. Deletion of these residues (CaMKI296, CaM-
KI293) did not block nuclear entry of CaMKI-a. A partial
disruption in nuclear translocation of CaMKI-a resulted from
mutation of residues K263R264, suggesting that these residues
may comprise part of a NLS. These residues are conserved
across the CaM kinase family and in protein kinase A [27] and
may, therefore, have a functional role in the kinase. Import of
NLS-cargo is mediated by importin-a, which binds to the NLS
and then forms a complex with importin-b that carries the
cargo through the nuclear pore [35]. CaMKI-a does not ap-
pear to bind to importin-a in vitro [32]. Thus, CaMKI-a may
interact with other members of the nuclear import machinery
or may enter the nucleus coupled to other NLS-cargo(s).
Further analysis of nuclear import mutants of CaMKI-a is
required to understand fully the mechanism by which CaMKI-
a translocates to the nucleus.These studies indicate that the cytoplasmic localization of
CaMKI-a is highly dependent on eﬃcient CRM1-mediated
nuclear export. Furthermore, the in vitro results showing an
increased interaction of CaMKI-a with the CRM1 complex in
the presence of Ca2þ/CaM suggest that activation of the kinase
may enhance the eﬃciency of nuclear export. Thus, multiple
cellular processes are required to maintain the steady-state
280 D.R. Stedman et al. / FEBS Letters 566 (2004) 275–280localization of CaMKI-a in the cytosol and not in the nucleus.
This implies that cytosolic substrates of CaMKI-a are likely
the most physiologically relevant. Notably, the best charac-
terized substrates for CaMKI-a are cytosolic, including syn-
apsin I and II [11], the cystic ﬁbrosis transmembrane
conductance regulator [12], myosin II regulatory light chain
kinase [8], and the translation initiation factor eIF4GII [10].
Other evidence suggests a role for cytoplasmic CaMKI in cell
cleavage progression in Xenopus oocytes [36] and in actin ﬁl-
ament reorganization in mammalian cells [8]. Recently, it has
been reported that cytosolic CaMKI-a is involved in growth
cone motility and axon outgrowth in neonatal cerebellar
granule neurons [6], supporting a role for CaMKI-a in signal
transduction at the cytoskeleton/plasma membrane interface.
In vitro, a number of nuclear substrates for full length
CaMKI have been identiﬁed including CREB [13] and ATF-1
[14]; however, in vivo eﬃcient export of CaMKI-a may also be
important for restricting its access to nuclear substrates, es-
pecially transcription factors. Ca2þ/CaM kinase-dependent
regulation of gene transcription may also be restricted to
particular cell types. Expression of CaMKIV, a kinase with
well-deﬁned eﬀects on transcription factor activity [34], is re-
stricted to sub-populations of neurons [37], while CaMKI is
ubiquitously expressed [16]. Although CaMKI-a is rarely de-
tected in the nucleus, a role for the kinase in phosphorylation
of nuclear substrates under some physiological circumstances
cannot be completely ruled out.
Several studies examining the role of CaMKI-a have used
the truncated, constitutively active form of the enzyme. This
truncation lacks a NES and is therefore localized uniformly to
both the cytoplasm and nucleus. In light of the data presented
here, it may be necessary to revisit these studies, particularly
those which implicate CaMKI-a in phosphorylation of nuclear
substrates, to determine their physiological relevance.
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